GlassScriptPhysician profile
Aaron Michael Rosenberg
NPI 1306237417
$20,813.02
in general payments reported to CMS, 2019-2025
27 companies · $559 in 2025
The $559 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,435 · 2020: $5,643 · 2021: $4,080 · 2022: $2,105 · 2023: $5,275 · 2024: $716 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Travel and Lodging: $2,186 · Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Travel and Lodging | $2,185.96 |
| Food and Beverage | $2,163.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,425.61 | 2019-2025 | Vraylar, Mavyret |
| Allergan, INC. | $6,830.32 | 2019-2020 | |
| Gilead Sciences, INC. | $899.48 | 2019-2025 | |
| Lilly USA, LLC | $569.90 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Orexo US, INC. | $440.30 | 2019-2025 | Zubsolv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.88 | 2021-2025 | Caplyta |
| Indivior INC. | $201.76 | 2019-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $193.05 | 2019-2025 | Trintellix |
| Corium, LLC | $184.87 | 2024 | Azstarys |
| Alkermes, INC. | $162.02 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $128.91 | 2020-2025 | Rexulti |
| Uswm, LLC | $73.45 | 2022-2023 | Lucemyra |
| Lundbeck LLC | $62.96 | 2021-2024 | Rexulti |
| Biodelivery Sciences International, INC. | $50.40 | 2019-2020 | |
| Braeburn INC. | $40.56 | 2024 | Brixadi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.18 | 2023 | Myrbetriq, Veozah |
| Axsome Therapeutics, INC. | $30.47 | 2024 | Auvelity |
| Amarin Pharma, INC. | $30.33 | 2020 | |
| Pfizer INC. | $30.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.48 | 2025 | Xifaxan |
| Biogen, INC. | $22.05 | 2025 | Leqembi |
| Heartflow, INC. | $21.57 | 2024 | |
| Eisai INC. | $20.68 | 2021 | |
| Bausch Health US, LLC | $20.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.51 | 2021 | |
| Shionogi INC | $18.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.